361 related articles for article (PubMed ID: 27399673)
1. Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions.
Lee DW; Lee KH; Kim JW; Keam B
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399673
[TBL] [Abstract][Full Text] [Related]
2. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Gong L; Xiong M; Huang Z; Miao L; Fan Y
Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
[TBL] [Abstract][Full Text] [Related]
4. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
[TBL] [Abstract][Full Text] [Related]
5. Leptomeningeal metastases of solid cancer.
Le Rhun E; Galanis E
Curr Opin Neurol; 2016 Dec; 29(6):797-805. PubMed ID: 27661208
[TBL] [Abstract][Full Text] [Related]
6. [Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
Kullmann T; Gauthier H; le Maignan C; Szabó A; Culine S
Orv Hetil; 2012 Sep; 153(35):1385-8. PubMed ID: 22935431
[TBL] [Abstract][Full Text] [Related]
7. Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series.
Chahal J; Stopeck A; Clarke K; Livingston RB; Chalasani P
Neurol Sci; 2015 Sep; 36(9):1691-3. PubMed ID: 25990104
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
9. Association of MRI findings with clinical characteristics and prognosis in patients with leptomeningeal carcinomatosis from non-small cell lung cancer.
Ko Y; Gwak HS; Park EY; Joo J; Lee YJ; Lee SH; Kwon JW; Shin SH; Yoo H
J Neurooncol; 2019 Jul; 143(3):553-562. PubMed ID: 31089925
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.
Ariyasu R; Horiike A; Koyama J; Saiki M; Sonoda T; Kawashima Y; Takano N; Oguri T; Nishikawa S; Kitazono S; Yanagitani N; Ohyanagi F; Nishio M
Anticancer Drugs; 2017 Jun; 28(5):565-567. PubMed ID: 28225456
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
[TBL] [Abstract][Full Text] [Related]
12. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Gwak HS; Joo J; Kim S; Yoo H; Shin SH; Han JY; Kim HT; Lee JS; Lee SH
J Thorac Oncol; 2013 May; 8(5):599-605. PubMed ID: 23422833
[TBL] [Abstract][Full Text] [Related]
13. [Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].
Cochereau D; Da Costa S; Le Maignan C; Gauthier H; Cochereau J; Espié M; Giacchetti S; Teixeira L
Bull Cancer; 2016 May; 103(5):444-54. PubMed ID: 26987841
[TBL] [Abstract][Full Text] [Related]
14. Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Kosmas C; Malamos NA; Tsavaris NB; Stamataki M; Gregoriou A; Rokana S; Vartholomeou M; Antonopoulos MJ
Oncology; 2002; 63(1):6-15. PubMed ID: 12187065
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.
Mego M; Sycova-Mila Z; Obertova J; Rajec J; Liskova S; Palacka P; Porsok S; Mardiak J
Breast; 2011 Oct; 20(5):478-80. PubMed ID: 21700455
[TBL] [Abstract][Full Text] [Related]
16. Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer.
Raj KP; Sanati H; Mehta RS; Zell JA
Anticancer Drugs; 2009 Apr; 20(4):301-4. PubMed ID: 19247177
[TBL] [Abstract][Full Text] [Related]
17. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.
Remon J; Le Rhun E; Besse B
Cancer Treat Rev; 2017 Feb; 53():128-137. PubMed ID: 28110254
[TBL] [Abstract][Full Text] [Related]
18. Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.
Kosmas C; Malamos NA; Tsavaris NB; Stamataki M; Stefanou S; Gregoriou A; Rokana S; Vartholomeou M; Antonopoulos MJ
J Neurooncol; 2002 Feb; 56(3):265-73. PubMed ID: 12061734
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer.
Mrugala MM; Kim B; Sharma A; Johnson N; Graham C; Kurland BF; Gralow J
Clin Breast Cancer; 2019 Oct; 19(5):311-316. PubMed ID: 31175053
[TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
